<DOC>
	<DOCNO>NCT00126633</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving gemcitabine cisplatin together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine cisplatin together bevacizumab work treat patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Bevacizumab Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time disease progression patient previously untreated metastatic adenocarcinoma pancreas treat gemcitabine , cisplatin , bevacizumab . - Determine safety toxicity regimen patient . Secondary - Determine objective response rate patient treat regimen . - Determine efficacy regimen , term proportion patient ≥ 50 % decline CA19-9 biomarker , patient . - Determine median survival patient treat regimen . - Correlate serum marker angiogenesis circulate tumor micrometastases clinical outcome patient treat regimen . OUTLINE : This open-label , non-randomized study . Patients receive gemcitabine IV 100 minute , cisplatin IV 30-60 minute , bevacizumab* IV 30-90 minute day 1 15 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients may receive additional study treatment discretion investigator . NOTE : *Patients may continue receive component therapy bevacizumab discontinue due toxicity . After completion study treatment , patient follow 28 day monthly thereafter . PROJECTED ACCRUAL : A total 36 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Must document extrapancreatic metastasis Radiographically measurable disease require Previously untreated disease No CNS brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( transfusion epoetin alfa [ Epogen® ] support allow ) No evidence bleed diathesis coagulopathy Hepatic INR ≤ 1.5 ( except patient receive fulldose warfarin ) Bilirubin ≤ 2.0 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal Creatinine ≤ 2.0 mg/dL Urine protein : creatinine ratio ≤ 1 Cardiovascular No New York Heart Association class IIIV congestive heart failure No myocardial infarction stroke within past 6 month No uncontrolled hypertension ( i.e. , blood pressure &gt; 160/110 mm Hg despite antihypertensive therapy ) No unstable angina No unstable symptomatic arrhythmia require medication Patients chronic atrial arrhythmia ( i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ) eligible No peripheral vascular disease ≥ grade 2 Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No significant traumatic injury within past 28 day No serious nonhealing wound , ulcer , bone fracture No malignancy within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix No serious systemic disease No history disease , metabolic dysfunction , physical examination finding , clinical laboratory find would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery More 28 day since prior major surgery , open biopsy More 7 day since prior fine needle aspiration core biopsy No concurrent major surgery Other No prior therapy , include systemic investigational therapy , locally advanced metastatic pancreatic cancer Treatment give adjuvant setting ( e.g. , radiotherapy and/or chemotherapy , give either concurrently systemically ) consider prior therapy provide progressive disease occur &gt; 6 month completion prior treatment Concurrent continuation therapeutic dos warfarin lowmolecular weight heparin allow pulmonary embolism , deep vein thrombosis , atrial fibrillation , clinical indication provide patient stable dose ≥ 28 day clot bleeding complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>